| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7666654 | Revue Francophone des Laboratoires | 2006 | 6 Pages |
Abstract
Hairy cell leukemia (HCL) accounts for 2 % of all haematologic cancers. The diagnosis is based on the identification of hairy cells in the peripheral blood and/or bone marrow. Hairy cells are B-cells which express CD 103 and DBA-44 without expressing CD5. No specific genetic abnormality was described in HCL and it is necessary to distinguish HCL from all other B-cell chronic lymphoproliferative disorders because specific treatment is required. The optimal treatment is debatable. Interferon-alpha 2a was the first new drug which considerably changed the management of patients with HCL. Purine analogs, 2â²-deoxycoformycin or 2-chloro-deoxyadenosine are very active and preferred. However the risk of cytopenia, immunosuppression and second cancer must be evaluated care-fully.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Mikaël Roussel, Michèle Malet, Xavier Troussard,